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Marijuana derived from cannabis sativa (Moraceae�� 
has �een one of the oldest psychoactive and healing 
su�stances widely used �y men for many centuries. In 
contemporary medicine these su�stances are still ap-
plied in such complications like nausea related to che-
motherapy�� and used as an appetite stimulator in AID� 
patients. Moreover�� canna�inoid receptor antagonists 
are currently used in o�esity treatment [��� �].
�tudies on the rational use of canna�inoids have 
grown up recently and to a great extent have �een 
related to the discovery of two canna�inoid recep-
tors�� CB� and CB�. CB� receptors are expressed 
predominantly in the �rain�� whereas CB� receptors 
are found primarily in the cells of the immune system 
[6�� ���� ���� �4]. Furthermore�� endogenous ligands for 
these receptors have also �een discovered and called 
endocanna�inoids [4]. The physiological interactions 
of this system in the field of immunology and carcino-
genesis remain unclear. 
B-cell chronic lymphocytic leukaemia �CLL�� 
is a disease characterised primarily �y defects in 
programmed cell death regulation [��]. CLL is still 
considered an incura�le disease. �o far great efforts 
have �een undertaken to improve the results of CLL 
treatment and finally eradicate this disease. 
Our former study showed an existence of signifi-
cant differences in canna�inoid receptors expression 
�etween CLL patients and healthy individuals. A higher 
percentage of B-lymphocytes expressing canna�inoid 
receptors and their higher fluorescence intensity as-
sessed �y flow cytometry �FC�� in the CLL patient group 
suggest that the canna�inoid system may take part in 
CLL development [�6].
The aim of our study was the assessment of can-
na�inoid receptor expression on the lymphocytes B in 
�one marrow trephine �iopsy �BMT�� derived from pa-
tients with diagnosed chronic lymphocytic leukaemia. 
The influence of purine nucleoside analogues treat-
ment �fludara�ine or �-chlorodeoxyadenosine�� on the 
canna�inoid receptors expression was evaluated.
Materials and Methods
The studied specimens were o�tained from �8 pre-
viously untreated CLL patients and �3 of the patients 
after the treatment with purine nucleoside analogues 
containing regimens �fludara�ine�� n = ���� �-chloro-
deoxyadenosine�� n = 6��. The study was approved �y 
the local Ethic Committee and all evaluated su�jects 
signed the consent for the study. The individuals�� fe-
males and males aged 3� to ����� were in II�IV clinical 
stage of the disease according to Rai staging system. 
BMT was performed in every patient as initial exami-
nation prior to chemotherapy and after six courses of 
treatment. Bone marrow tissue was taken routinely 
from the posterior iliac spine using the Jamshidi type 
needle. The sample was fixed in the so called Ox-
ford solution ���� ml of 4�% formaldehyde solution�� 
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��� ml of destilated water�� 8.�� g NaCl�� �� ml of acetic 
acid glacial�� for 48 h. After fixing�� the representa-
tive trephine specimens were put into paraffin �ars. 
� µm sections were cut using microtom. In the BMT�� 
morphology was analysed on standard haematoxylin 
and eosin stained sections. The origin of neoplastic 
cells forming infiltration was confirmed �y coupling 
with antiCD�� monoclonal anti�ody �DAKO�� catalog 
No M�������. For identification of other leukocytes we 
used MAC 38�� monoclonal anti�ody �DAKO�� catalog 
No M���4����. The canna�inoid receptors were detected 
using specific primary polyclonal CB� anti�ody �CB��� 
catalog No PA�-��4��� Affinity BioReagents; Golden�� 
Co�� U�A�� and CB� anti�ody �CB� receptor polyclonal 
anti�ody�� catalog No. �������� Cayman Chemical�� Ann 
Ar�or�� U�A�� in dilution � : �� and � : ����� respectively. 
All sections required microwave heating for receptor 
retrieval. Primary anti�odies were visualised �y the 
�iotin-streptavidin-peroxidase method using L�AB + 
HRPkit with DAB �3��3-diamino�enzidine��. The positive 
reaction was seen as a �rown colour. For negative 
control the sections underwent the a�ove procedure 
without primary anti�odies. Positive control for CB� 
and CB� anti�odies was performed using lymph node 
slices o�tained from T cell lymphoma patient. The 
intensity of immunohistochemical �IHC�� staining was 
defined as negative�� weak staining�� moderate staining 
and strong staining.
The percentage of lymphoid cells with the positive 
reactions was assessed using morphometric analy-
ser set MicroImage �OLYMPU��� with Analysis DP�� 
program. 
Flow cytometry assessment of a�errant CLL phe-
notype and canna�inoid receptor expression were 
performed in all patients at the time of diagnosis 
�n = �8��. Additionally�� �one marrow FC assessment 
was performed in 3 cases �efore the treatment. To 
confirm a specific phenotype commercially availa�le 
monoclonal anti�odies �Becton Dickinson�� were used. 
CB� and CB� human canna�inoid receptors polyclonal 
anti�ody �affinity pure�� were o�tained from Cayman 
Chemical. All the other reagents were o�tained from 
Coulter. For flow cytometric analysis � x ����� x ��6 
peripheral �lood cells �n = �8�� or �one marrow �n = 
3�� were incu�ated with �� µl of anty-CB� or anty-CB� 
anty�odies for 3� min�� in the dark�� at 4 °C. Then�� �� µl 
of monoclonal anti�odies IgG�-FITC and CD��-PE 
were added and samples were incu�ated for �� min�� 
in the dark�� at 4 °C. Then samples were lysed�� fixed 
and sta�ilized using Immuno-Prep �Coulter procedure�� 
and estimated �y flow cytometry �Epics XL�� Coulter��. 
Percentage and mean fluorescence intensity �MFI�� 
were assessed. 
All results are presented as mean ± �EM. Distri�u-
tion of varia�les in every study group was evaluated 
via the �hapiro-Wilk test and the differences �etween 
study groups �with nonparametric distri�ution�� were 
assessed with the use of Wilcoxon’s test. 
results 
The results showed that the neoplastic infiltration at 
the time of diagnosis was very extensive and amounted 
to 8�.� ± �.3%. Both types of canna�inoid receptors 
were expressed on the surface of neoplastic cells 
infiltrating �one marrow. The expression of CB� re-
ceptor was significantly lower than that of CB� ����.� ± 
3.�% and ��.� ± �.��% respectively�� p < �.�����. In all 
the cases an existence of canna�inoid receptors was 
confirmed �y FC�� and we o�served very high percent-
ages of �oth CB�/CD�� and CB�/CD�� positive cells in 
all patients �8�.6�� ± 8.6% and 86.66 ± �.6 respectively�� 
p = �.�3��. However�� MFI for CB� receptor was statisti-
cally significantly lower than CB� ��.84 ± �.��% and 
6.�3 ± �.� respectively�� p = �.������. No differences in 
CLL phenotype and canna�inoid receptor expression 
were o�served depending on the source of �lood cells 
�peripheral �lood or �one marrow��.
Nine of the patients responded to the applied 
treatment with a statistically significant reduction in 
leukaemic infiltration �����.� ± 6.�% to 3�.� ± 6.�%�� p = 
�.������ and the reduction of CB� receptor expression 
��4.4 ± 4.8% to 8.6 ± �.�%�� p = �.������ �ut there was 
no change in CB� expression ���.�� ± �.��% vs ��.� ± 
�.8%�� p = �.6���. 
Four patients without remission presented no 
changes in canna�inoid receptors expression after 
treatment. 
In all of the investigated cases the anti�odies 
against �oth canna�inoid receptor types gave positive 
immunohistochemical reaction. A diversity in inten-
sity of the reaction was o�served. At the diagnosis 
the intensity of CB� and CB� receptors was mainly 
weak and strong�� respectively. In spite of a decrease 
in neoplastic infiltration of the responders the treat-
ment did not affect the pattern of anti�ody-staining 
intensity. The same phenomenon was o�served in 
non responders. 
The immunohistochemical staining of the selected 
trephine specimens is presented on the Figures �elow 
�Fig. �����. An example of FC canna�inoid receptor 
analysis is shown in Fig. 6.
disCussion
Normal cells of the immune system express high lev-
els of CB� receptors. Those receptors play an important 
role in the B-cells differentiation [3�� ���]. However�� up to 
date�� there has �een insufficient data concerning the 
presence of canna�inoid receptors on the transformed 
immune cells in CLL patients. This study confirms the 
existence of �oth types of canna�inoid receptors on the 
neoplastic lymphocyte surface in the CLL patients. 
Previous studies of Galiegue et al. [�] using RT-PCR 
method showed that CB� receptor is a�undant in hu-
man �lood cells with the expression level ������-fold 
higher than that of CB�. Further o�servation of McKa-
lip et al. [�3] indicated the presence of CB� receptors 
in human leukaemia and lymphoma cell lines [��� �3]. 
However�� they did not detect the presence of CB� re-
ceptors. Other authors also reported a high density of 
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fig. 1. Bone marrow trephine �iopsy section. Diffuse infiltration 
in CLL. Bone tra�ecula and sinus in centre. Paraffin — em�ed-
ded�� H & E�� x �4�
fig. 3. Bone marrow trephine �iopsy section�� CLL. Lymphoid 
cells with positive staining for CB� anti�ody — after treatment. 
�trong positive staining of single cells. Immunohistochemical 
staining �CB��� x 48���
fig. 5. Bone marrow trephine �iopsy section�� CLL. Bone marrow 
hypoplasia. �ome cells with positive staining for CB� anti�ody. 
Immunohistochemical staining �CB��� x �4���
fig. 2. Bone marrow trephine �iopsy section�� CLL. Lymphoid 
cells with positive staining for CB� anti�ody — �efore treatment. 
Immunohistochemical staining �CB��� x 48���
fig. 4.Bone marrow trephine �iopsy section. Diffuse infiltration 
in CLL. The majority of cells with characteristic expression of CB� 
receptors �moderate staining�� - �efore treatment. Immunohisto-
chemical staining �CB��� x ������
fig. 6. An example of flow cytometry. �tudy presents co-expres-
sion of �oth canna�inoid receptors with CD��+ on lymphocytes in 
peripheral �lood of CLL patients. The majority of B-lymphocytes 
expressed canna�inoid receptors
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CB� receptors �y flow cytometry in the B-lymphocytes 
su�population [��]. Interestingly�� our study proved that 
leukaemic cells display a relatively high expression 
of CB� receptors. However�� similarly to o�servations 
made �y Galiegue et al. [�]�� this expression was lower 
than that of CB�. It is worth mentioning that�� accord-
ing to one report �y Islam et al [��]�� neoplastic cells in 
mantle cell lymphoma present a very high expression 
of CB� receptors. Our findings indirectly confirm the 
very high density of CB� receptors through the inten-
sity of the immunohistochemical reaction/staining. 
In the case of CB� receptors this intensity was much 
lower. In fact�� we found in FC analysis equal percentage 
of lymphocytes that present CB� and CB� receptors 
on their surface. However�� the MFI that may express 
density of the receptor was statistically higher for CB�. 
As we know the FC may �e more specific in assessment 
of particular molecules when their density is low [�8]. 
�o�� difference �etween IHC and FC assessment of 
canna�inoid CB� receptor may reflect its relative low 
density on the cell surface. 
Other peripheral �lood mononuclear cells may ex-
press canna�inoid receptors on their surface [3�� ���]. 
To make sure that we analysed lymphocytes the IHC 
included CD���+�� and CD3���� staining on serial sec-
tions and flow cytometry analysis of neoplastic cells in 
peripheral �lood �all cases�� and �one marrow �3 cases�� 
were performed. 
Up to date there has �een no evidence of the influ-
ence of chemotherapy on the canna�inoid receptors 
expression in the CLL patients. The reduction of the 
leukaemic �one marrow infiltration after purine ana-
logues treatment did not affect the CB� expression. 
In contrast�� we noted a significant reduction in the ex-
pression of CB� receptors after the chemotherapy. 
In some of the patients who did not respond to the 
treatment�� no changes in CB� receptor expression were 
o�served. Micro-array analysis of gene expression 
profile of CLL patients performed �y Haslinger et al. 
[8] showed that CB� receptor is differently expressed 
�upregulated�� within the group with ��q����3 deletion. 
In our study�� we did not perform analysis of cytogenetic 
changes that could reveal whether the individuals that 
did not respond to the treatment and presented no 
changes in CB� expression �elong to the group of pa-
tients with poor prognosis due to the deletion.
There are two splice variants of CB� receptor 
discovered in human tissues. The application of the 
polyclonal anti�ody was not helpful to differentiate 
�etween the variants. The CB � anti�ody recognised 
the C terminal amino acid fragment of the canna�inoid 
CB� human receptor. The production of C�� anti�odies 
has �een �ased on a sequence �etween the N-terminus 
and the first transmem�rane domain of the receptor 
[�]. The existence of distinct conserved sequence of 
amino acids �etween CB� and CB� receptors in these 
regions excludes the possi�ility of cross-reactions of the 
anti�odies. The applied indirect immunohistochemical 
technique did not allow for performing simultaneous 
assessment of �oth canna�inoid receptors. 
In conclusion�� our study provides original evidence 
for the existence of canna�inoid receptors on lympho-
cytes B in CLL patients. CB� receptor expressed in 
great num�er on the neoplastic cells may �e conside-
red a new particular surface structure modifying the 
course of the disease. The presence of CB� receptor 
on the neoplastic lymphocytes after chemotherapy 
may �e considered as a new target in the treatment of 
residual disease. Elucidating and understanding the 
role of endocnna�inoid system in leukaemia genesis 
could give us an additional possi�ility in fighting against 
chronic lymphocytic leukaemia. 
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экспрессия� ре�еп��р��� к�����и��и����   
�� �реп����и�п������ к�с����� ����� ��������     
��р��ически� �и����е�к���� п�с�е �ече�ия�    
пури������и ��������и  
Обоснование: рецепторы каннабиноидов CB1 и CB2 �в���т�� �а�т�� �и�те�ы �ндоканнабиноидов, котора� и�рает ва�н��          
ро�� в проце��ах про�иферации и апоптоза раз�и�ных неоп�а�ти�е�ких к�еток. Одни� из забо�еваний, при которых про-
и�ходит нар�шение �тих проце��ов, �в��ет�� В-к�ето�ный хрони�е�кий �и�ф�ейкоз. Цель: оценка �к�пре��ии рецепторов 
каннабиноидов на В-�и�фоцитах в трепанобиоптатах � бо��ных �ейкозо� до и по��е проведени� �е�ени� � и�по��зование� 
п�риновых ана�о�ов. Методы: биоптаты по���и�и р�тинны�и �етода�и; и���но�и�тохи�и�е�кое и���едование депара-
финизированных �резов проводи�и по �тандартной процед�ре. Рецепторы каннабиноидов опреде���и � и�по��зование� 
�пецифи�е�ких �онок�она��ных антите� анти-CB1 и анти-CB2. �ро�е то�о, на�и�ие рецепторов подтвер�дено при по-         
�ощи прото�ной цитоф��ори�етрии. Результаты: показано, �то �к�пре��и� рецептора CB1 на поверхно�ти оп�хо�евых    
к�еток ни�е, �е� �к�пре��и� CB2 (17,0 ± 3,1% и 92,1 ± 1,7% �оответ�твенно,         p < 0,001). По��е проведенно�о �е�ени� 
� 9 пациентов от�е�а�о�� ��ен�шение �ейкозно�о инфи��трата (77,2 ± 6,9% до 30,2 ± 6,5%,      p = 0,007) и �ни�ение �к�-
пре��ии рецептора CB1 (24,4 ± 4,8% до 8,6 ± 2,9%,        p = 0,01), однако раз�и�ий в �к�пре��ии CB2 не от�е�а�и (91,7 ±     
2,7% против 90,9 ± 2,8%,  p = 0,69). У 4 пациентов, � которых не �да�о�� до�ти�� ре�и��ии, опреде���и да�е повышение 
�к�пре��ии рецепторов. Во в�ех ����а�х �аркировки антите�а�и к обои� типа� рецепторов каннабиноидов от�е�а�и по�о-
�ите��н�� реакци�. Бо�ее то�о, при��т�твие рецепторов каннабиноидов на з�ока�е�твенных к�етках подтвер�да�и при 
по�ощи прото�ной цито�етрии. Выводы: в ходе и���едовани� показано изна�а��ное на�и�ие рецепторов каннабиноидов 
на В-�и�фоцитах � бо��ных хрони�е�ки� �и�фо�ейкозо�. Указанные рецепторы �о��т быт� новой �тр�кт�рой, котора� 
�о�ет быт� �одифицирована в те�ение бо�езни, и �о��т ��итат��� новой �ишен�� при �е�ении бо��ных �ейкозо�. 
Ключевые слова: хрони�е�кий �и�фо�ейкоз, �и�те�а �ндоканнабиоидов, п�риновые ана�о�и, рецепторы каннабиоидов, 
трепанобиоп�и�.
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